VIDA Diagnostics announced Thursday, July 25, that it has received an investment of $1 million and additional support from UnityPoint Health Ventures on behalf of Iowa’s UnityPoint Health healthcare system.
VIDA and UnityPoint Health will work together to “develop and commercialize” VIDA’s AI-powered LungPrint solution, which analyzes chest CT scans and flags abnormalities.
“VIDA's partnership with UnityPoint Health represents a shared vision for improving care to patients through higher quality, highly informed, yet affordable solutions through the influx of transformative innovations like LungPrint,” Susan A. Wood, PhD, CEO of VIDA, said in a prepared statement. “Together we are able to broaden access to our game-changing solutions and deliver exceptional patient care.”
“At UnityPoint Health, we're dedicated to making it easier to live well,” Matthew Warrens, managing director at UnityPoint Health Ventures, said in the same statement. “Incorporating technological innovations such as VIDA's LungPrint is an important part of that vision. We're thrilled to work with VIDA to bring this technology to our patients and providers.”
VIDA will also receive funds from the Iowa Economic Development Authority as a part of this arrangement.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.